ClinicalTrials.gg
RecruitingNCT07180407PIPUpdated Dec 2, 2025

The Post-ICU Pain Study

An observational study in Chronic Pain, Post Intensive Care Unit Syndrome and Quality of Life, sponsored by Zealand University Hospital. Recruiting at 4 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Zealand University Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Chronic Pain with a site in Denmark — 14 open to participants now, 16 under way, none of them phase 3. Chronic Pain · Denmark.

Planned enrollment
9th of 33
800 · median 134
Started
2025
with 2 others
Observational
33 of 90
6 open now
Primary completion
2027-01
later than 8 of 15 live
Registered
83rd of 90
by date

Among the 90 studies in Chronic Pain with a site in Denmark, this one is the 9th largest by planned enrollment of the 33 observational ones that give a count, is one of 3 that started in 2025, is one of 33 observational ones, reaches primary completion later than 8 of the 15 other live ones, and was the 83rd registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

14 of the 90 studies in Chronic Pain with a site in Denmark are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Chronic Pain with a site in Denmark, or all of them as a file.
02

Study summary

BACKGROUND: ICU survivors may experience serious psychological, physical and cognitive impairments following ICU admission, collectively termed Post Intensive Care Syndrome (PICS). Persistent pain is an underrecognized component of PICS. Previous research has shown that persistent pain is a profound clinical challenge in ICU survivors, however, research demonstrates conflicting results. Furthermore, no studies have examined the prevalence of persistent pain in ICU survivors in a contemporary Danish ICU setting.

OBJECTIVES: We aim to examine the clinical trajectory, risk factors, and pathophysiology of persistent pain in ICU survivors in Denmark.

DESIGN AND SAMPLE SIZE: The study is designed as a multicenter, prospective, inception cohort study with clinical follow-up. Based on the pre-study sample size calculation, 800 patients will be included. Patients will be contacted by telephone 90 days and 180 days after ICU discharge, and a series of questionnaires regarding pain, sleep quality, affective state and quality of life will be completed. A subgroup of patients will undergo a detailed clinical examination including quantitative sensory testing between 180-365 days after ICU discharge.

POPULATION: Patients will be recruited from 4 Danish ICU departments. Inclusion criteria include adult patients (18 years of age), acute admission to the ICU, and an ICU admission of a minimum of 48 hours.

OUTCOMES: The primary outcome is the prevalence of pain assessed by the Brief Pain Inventory (BPI) at 90 and 180 days after ICU discharge. Secondary outcomes include additional detailed descriptions of pain and daily activity, sleep quality, affective state, quality of life, treatment- and patient-related risk factors, and biomarkers associated with development of persistent pain.

Substudies:

- QST substudy: 80 participants (40 with pain and 40 without pain) recruited from the main cohort will undergo Quantative Somatosensory Testing (QST). The objectives are first, to delineate somatosensory profiles of ICU survivors with and without pain, and second, to examine the presence of neuropathic pain in ICU survivors.

03

Conditions studied

  • Chronic Pain
  • Post Intensive Care Unit Syndrome
  • Quality of Life
  • Pain Disorder

Keywords

  • intensive care units
  • chronic pain
  • sleep disorder
  • anxiety and depression
  • icu survivors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to the ICU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult ICU patients ≥18 years of age
  • Acute admission to the ICU
  • ICU length of stay of at least 48 hours

Exclusion criteria

Exclusion Criteria:

  • Patients transferred from a non-participating ICU
  • Patients with pre-planned admission to the ICU e.g., following elective surgery
  • Patients unable to complete questionnaires, including those who are unable to understand or speak Danish, or patients with severe cognitive deficits.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Prevalence of pain

    Patients are defined as having pain if they answer "yes" to question number 1 in the Brief Pain Inventory - Short Form

    Time frame: 180 day follow-up

Secondary outcomes

  1. Brief Pain Inventory - Short Form (BPI-SF)

    Additional components of the Brief Pain Invenstory Short Form

    Time frame: At follow-up at 90 and 180 days

  2. Incidence of new-onset persistent pain after ICU discharge

    Definition of new-onset persistent pain: Individuals presenting with pain according to Brief Pain Inventory Short Form at 90 AND 180 days follow-up AND not suffering from persistent pain/using pain medication regularly before ICU admission, as reported by the individual.

    Time frame: at 90 and 180 days follow-up

  3. Quality of life measured by EuroQol-5-domain 5-level (EQ-5D-5L)

    The EQ-5D-5L comprises 5 components (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression) which can be rated at 5 levels. Furthermore, a Visual Analog Scale (VAS) documents self-rated health

    Time frame: at 90 and 180 days

  4. The Single Item Sleep Quality Scale (SQS)

    The respondent is asked to rate the overall quality of sleep over a 7-day recall period on a VAS. Respondents are instructed to consider the following components before answering the questionnaire: hours of sleep, night wakings, how easily they fall asleep, how often they wake earlier then needed, and how refreshed they feel when waking. Sleep quality is scored as follows: 0 = terrible, 1-3 = poor, 4-6 = fair, 7-9 = good, and 10 = excellent

    Time frame: at 90 and 180 days

  5. Hospital Anxiety and Depression Scale (HADS)

    It comprises seven questions regarding anxiety and seven questions regarding depressive symptoms. Anxiety and depression are scored separately with recommended cut-off values of 8-10 for possible presence of a mood disorder and \>11 for probable presence of a mood disorder

    Time frame: at 90 and 180 days

  6. Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS)

    Only patients answering "yes" to the Brief Pain Inventory Short Form, question number 1, will be asked to fill out the S-LANSS. The tool was created as a clinical tool to identify pain primarily of neuropathic origin, allowing for the differentiation between neuropathic pain and nociceptive pain. It contains 7 items assessing pain quality, sensory changes and specific symptoms commonly associated with neuropathic pain. A score above 12 suggests neuropathic pain

    Time frame: 90 and 180 days

  7. 30-day mortality

    Time frame: 30 days

  8. 90-day mortality

    Time frame: 90 days

  9. 180 days mortality

    Time frame: 180 days

Other outcomes

  1. The Short Physical Performance Battery (SPPB)

    QST SUBSTUDY: This test includes a series of tasks designed to examine physical performance. The SPPB requires limited space and takes about 10 minutes to complete. It contains 3 domains (3 m gait speed, 5 times chair stands, and 3 progressive standing balance tasks). Each component is scored separately, and a total score is calculated. The maximum score is 12 indicating little to no mobility impairment

    Time frame: between 180 days followup and 360 days.

  2. PainDETECT (PD-Q)

    QST SUBSTUDY: The questionnaire assesses pain intensity (three questions), pain course patterns, the location of pain and presence of radiating pain (via a body chart), and sensory descriptors of pain (seven questions). Scores of 0-12 indicate neuropathic pain component is unlikely, scores of 12-18 indicates results are ambiguous, however a neuropathic component can pe present, and lastly scores of 19-38 indicates neuropathic pain component is likely

    Time frame: between 180 days followup and 360 days

  3. QST outcomes

    QST SUBSTUDY: \- simple reaction time (seconds)

    Time frame: between 180 days followup and 360 days

  4. QST outcomes

    QST SUBSTUDY: \- Thermal thresholds: Thresholds are determined by increasing the thermode temperature from baseline 32°C (ramp rate + 1.0 °C/s) until the subject activates the 'stop' button. WDT is defined as the point at which the patient first perceives a sensation of warmth. HPT is defined as the point at which the thermal sensation first turns into pain. The cut-off temperature is 50°C, avoiding the risk of thermal skin injuries

    Time frame: between 180 days followup and 360 days

  5. QST outcomes

    QST SUBSTUDY: \- Pinprick thresholds and temporal summation (mN)

    Time frame: between 180 days followup and 360 days

  6. QST outcomes

    QST SUBSTUDY: \- Offset analgesia (numeric rating scale; 0-100).

    Time frame: between 180 days followup and 360 days

  7. QST outcomes

    QST SUBSTUDY: \- Conditioned pain modulation (seconds): includes the cold pressor test (CPT; conditioning stimulus) and pressure algometry (test stimulus).

    Time frame: between 180 days followup and 360 days

07

Study locations

3 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 16 months is below that.

Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Sep 18, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jun 2027
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07180407
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Sep 23, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Dec 2, 2025

Study contacts

Bennedikte K Madsen, MD
Contact
bkom@regionsjaelland.dk
0045

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion